Eylea (Aflibercept) 8 mg

Eylea (aflibercept) 8 mg is now listed on the Pharmaceutical Benefits Scheme (PBS)1 for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) in adults, based on positive results from the pivotal PULSAR and PHOTON studies.2-4 

Eylea 8 mg treatment is initiated with one injection per month for three consecutive months, followed by one injection every eight to 16 weeks, based on the ophthalmologist's judgement of visual and/or anatomic outcomes.2 Treatment with intervals of one month for more than three consecutive months has not been studied.2 Safety of Eylea 8 mg was similar to Eylea 2 mg in both studies, with no new safety signals identified.2-4

Contact: Bayer Account Manager

Please review the Eylea product information before prescribing, available by scanning the QR code above
or contacting Bayer Medical Information on (AUS) 1800 008 757.

PBS Information: Eylea 8 mg: Authority required for the treatment of wet age-related macular degeneration and diabetic macular oedema. Eylea 2 mg: Authority required for the treatment of wet age-related macular degeneration, diabetic macular oedema, central retinal vein occlusion, branch retinal vein occlusion, and myopic choroidal neovascularisation. Refer to PBS schedule for full authority required information.

References

1. Pharmaceutical Benefits Scheme, available at: pbs.gov.au/medicine/item/14594D-14626T-14627W-14635G.
2. Eylea approved product information.
3. Lanzetta P, et al. Lancet 2024. doi: 10.1016/S0140-6736(24)00063-1.
4. Brown DM, et al. Lancet 2024. doi: 10.1016/S0140-6736(23)02577-1.

Integre Pro Scan

Lumibird Medical’s Integre Pro Scan is transforming retinal photocoagulation. It combines multi-colour photocoagulation with a precise computer-controlled pattern scanning laser in an ergonomically advanced all-in-one laser/slit lamp design.

Whether positioning focal treatment in the macular area, or performing panretinal photocoagulation in the periphery, Integre Pro Scan provides a comprehensive pattern and wavelength choice to cover all retinal pathologies.

Visit: ophthalmology.lumibirdmedical.com

iCare Eidon Family

The iCare Eidon is a cutting-edge retinal imaging system optimised for detecting and monitoring diabetic retinal diseases. It features a unique combination of confocal technology and white LED light, delivering ultra-high-resolution, TrueColor images with exceptional sharpness. This allows for accurate visualisation of diabetic retinopathy signs, such as microaneurysms, haemorrhages, and exudates – even through small pupils or media opacities. Its widefield imaging capability, up to 200°, enables comprehensive assessment of both the central and peripheral retina, which is essential for effective management of patients with diabetes. Its non-mydriatic design enhances patient comfort and streamlines workflow, making it ideal for routine screenings and to assist with advanced clinical diagnostics.

Contact: iCare (AUS) 0435 788 702

Sirius+ and Osiris Surgery Suite

The Sirius+ and Osiris surgery suite, with the dual benefit of both world-leading devices, enables your clinic to offer patients highly personalised surgery planning with ray tracing.

It includes pre- and post-operative pupil size and kappa angle evaluation, intraocular lens (IOL) calculations with ray tracing (even for patients that have undergone refractive surgery), IOL decentration (even for extended depth of focus IOLs), toric IOL simulations, Gaussian mapping for keratoconus screening, dynamic pupillography, advanced AI keratoconous screening, and gonioscopy.

The suite’s pyramidal wavefront sensor allows for 33 high resolution images per second, providing invaluable, high-precision data (without sampling). It also offers high-order aberration assessment of patients, dynamic accommodation behavioural assessments, advanced dry eye assessments, and more.

Visit: eyetek.com.au

KeepSight

The KeepSight programme, delivered by Diabetes Australia in partnership with the eye sector, is designed to increase the number of people with diabetes undergoing regular comprehensive eye examinations. In doing so, the programme helps detect eye problems that can lead to vision loss.

By sending reminders to registered patients, KeepSight makes it easier for people with diabetes to remember when they are due to get their eyes checked. The KeepSight reminders supplement existing recall and reminder systems within eye care practices.

As an eye care professional, you can help your patients with diabetes by introducing them to the KeepSight programme and, with their consent, record details of their eye check via Oculo or Optomate or the KeepSight website. Patients can also register themselves on the KeepSight website.

Visit: keepsight.org.au

Dream OCT

The Dream OCT is a next-generation optical coherence tomography (OCT) system that combines speed, depth, and multimodal imaging to elevate diagnostic precision. It’s ability to visualise the retina using multiple modalities offers a more complete view of disease, enhancing both diagnosis and management.

Suitable for a wider patient range, including up to -33D of accommodation, it delivers posterior imaging up to 12 mm and anterior segment depth of 16.2 mm. As the first OCT-angiography with ultra-widefield imaging over 200°, it enables confident detection of peripheral retinal lesions.

For patients with diabetes, its true angio algorithm provides accurate vascular detail, minimising false positives and negatives. With real-time scan speeds of up to 400,000 Hz, Dream OCT captures ultra-high-resolution images in just five seconds.

The Dream OCT was due to launch in Australia at ODMAFair25, subject to approval by the Australian Therapeutic Goods Administration.

Contact: Ophthalmopro (AUS) 1300 578 288

Dream OCT

Vabysmo (faricimab) is the only bispecific antibody on the Australian Register of Therapeutic Goods for neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO), and macular oedema secondary to retinal vein occlusion (RVO).1,2

Vabysmo is now Pharmaceutical Benefits Scheme (PBS) listed for RVO, alongside its listings for nAMD and DMO.3

This intravitreal treatment works on two distinct pathways, specifically recognising and blocking angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF).1 After at least three initial four-weekly loading doses for RVO or four initial loading doses for nAMD and DMO, the frequency of ongoing injections may be extended up to every 16 weeks, based on the patient’s anatomic and/or visual outcomes.1,4,5

Contact: Ophthalmopro (AUS) 1300 578 288

ZEISS Retina Workplace

Detect and treat macular disease with a multi-modality approach, combining ultra-widefield retina imaging, optical coherence tomography (OCT), and OCT angiography (OCT-A).

ZEISS Retina Workplace is the first integrated multi-modality software that enables the user to register Clarus ultra-widefield images with Cirrus OCT cube, or raster scans, and OCT-A images. This capability affords the visualisation of integrated imaging data, all on one screen, in seconds.

ZEISS Retina Workplace synchronises data so the user can detect and compare macular disease change over time.

Users can compare up to three exams on a single screen and document treatment decisions over time to also visualise treatment efficiency for the patient. ZEISS Retina Workplace also includes ZEISS advanced retinal pigment epithelium analysis for geographic atrophy assessment for a complete solution to managing macular disease.

Contact: ZEISS Account Manager